TrialPath

Find a study

Browse recruiting studies near you — free to check, always your choice.

Match me to a study

43 studies

Recruiting now, in plain language. Every study is watched over by an independent ethics board.

ListMap
Weight & metabolicPeptide & GLP-1Mental healthLungs & breathingHeart & circulationKidneyBrain & memoryBlood disordersImmune & autoimmuneSkin

41 studies on the map

Molecular Signatures of Cutaneous Dupilumab Response — University of California, San Francisco, San FranciscoSafety and Efficacy of EXV-802 and EXV-801 in the Treatment of Agitation in Alzheimer's Disease Dementia — Esperanza Clinical, MurrietaA Study of the Medicine Called Abrocitinib in Children 6 to Less Than 12 Years of Age With Moderate-to-Severe Eczema — Cahaba Dermatology & Skin Health Center, LLC, BirminghamA Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease — Healthy Brain Clinic, Long BeachDupilumab De-escalation in Pediatric Atopic Dermatitis — Johns Hopkins Univerisity, BaltimoreA Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3) — Local Institution - 2609, ChandlerSex-Specific Effects of Endocrine Disruption on Aging and Alzheimer's Disease — Mayo Clinic, JacksonvilleA Study of Donanemab (LY3002813) in Participants Who Completed Study AACM (TRAILBLAZER-ALZ 3-EXT). — Banner Alzheimer's Institute, PhoenixA Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease — Banner Alzheimer?s Institute, PhoenixA Study to Evaluate Safety and Efficacy of KarXT + KarX-EC as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-5) — Gilbert Neurology Partners/CCT Research, GilbertLebrikizumab in Moderate-to-severe Atopic Dermatitis — Physioseq USA - CA, FolsomAβ Dynamics in LLMD — NYU Langone Health, New YorkA Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis — Applied Research Center Of Arkansas /ID# 268547, Little RockEpidemiology and Biomarker Study in Alzheimer's Disease — Care Access - Houston, HoustonVisualizing Brain Proteinopathies Using [F-18]Flornaptitril-PET in the Prediction of Clinical Progression of Mild Cognitive Impairment With Either Suspected Chronic Traumatic Encephalopathy or Alzheimer's Disease — Endeavor Health Systems, EvanstonEthnic Differences in Mechanisms of Action of Dupilumab — University of Michigan, Ann ArborA Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2) — Fullerton Neurology and Headache Center, FullertonA Study to Investigate Safety and Efficacy of Tapinarof Cream, 1% in Participants Ages 3 Months to < 24 Months With Atopic Dermatitis — AllerVie Clinical Research, BirminghamPET Imaging Tau Accumulation in FTLD and Atypical Alzheimer's Using [18F]-PI-2620 — Perelman Center for Advance Medicine, PhiladelphiaA Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-2) — Chandler Clinical Trials, LLC, ChandlerA Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Children and Infants With Moderate-to-severe Atopic Dermatitis — Leo Pharma Investigational site, BirminghamA Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab — Cahaba Dermatology & Skin Health Center /ID# 263855, BirminghamA Study of Zunveyl on Safety, Tolerability, Neuropsychiatric Symptoms, and Caregiver Distress in Alzheimer's Disease (RESOLVE) — Tekton Research Saint Louis Psychiatry, St LouisA Phase 3 Study of Rezpegaldesleukin (NKTR-358) for Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic Dermatitis — Nektar Investigative Site, St. PetersburgA Study of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease — University of Alabama at Birmingham, BirminghamScreening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies — University of Alabama at Birmingham, BirminghamA Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4) — Local Institution - 1227, ChandlerBiomarker Exploration in Aging, Cognition and Neurodegeneration — University of California, Irvine, IrvineA Study of a Potential Disease Modifying Treatment in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation — University of Alabama in Birmingham, BirminghamMasupirdine for the Treatment of Agitation in Dementia of the Alzheimer's Type — Advanced Research Center, Inc., AnaheimElucidating the Role of Cholinergic Degeneration in Cognitive Fluctuations in Lewy Body Dementia — Virginia Commonwealth University, RichmondNighttime Agitation and Restless Legs Syndrome in People With Alzheimer's Disease — The University of Texas at Austin, AustinPreventing Alzheimer's With Cognitive Training — University of Florida, GainesvillePragmatic Evaluation of Events And Benefits of Lipid-lowering in Older Adults — University of Alabama at Birmingham, Birmingham[18F]PI-2620 Phase 3 Histopathological Study — Barrow Neurological Institute, PhoenixUsing Dupilumab to Improve Circadian Function, Sleep and Pruritus in Children With Moderate/Severe Atopic Dermatitis — Lurie Children's Hospital/Northwestern University, ChicagoDupixent and Narrowband UVB for Atopic Dermatitis — Eczema Treatment Center of New Jersey, East WindsorA Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation — University of Alabama in Birmingham, BirminghamComparing Antipsychotic Medications in LBD Over Time — University Health System, San AntonioA Long-term Study of the Medicine Called Abrocitinib in Children Aged 2 Years and Older With Moderate to Severe Eczema — Cahaba Dermatology & Skin Health Center, BirminghamA Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1) — Imaging Endpoints, Scottsdale